These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 25340395)
1. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395 [TBL] [Abstract][Full Text] [Related]
2. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients. Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800 [TBL] [Abstract][Full Text] [Related]
3. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Qiao W; Liu H; Guo W; Li P; Deng M Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638 [TBL] [Abstract][Full Text] [Related]
8. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. Chen Z; Chen X; Zhou E; Chen G; Qian K; Wu X; Miao X; Tang Z PLoS One; 2014; 9(4):e95475. PubMed ID: 24743335 [TBL] [Abstract][Full Text] [Related]
10. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435 [TBL] [Abstract][Full Text] [Related]
11. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488 [TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer]. Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866 [TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression]. Fan Y; Guan Y; Zhao WH; Li Q; Xu BH Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993 [TBL] [Abstract][Full Text] [Related]
17. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre. Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345 [TBL] [Abstract][Full Text] [Related]
18. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870 [TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis. Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103 [TBL] [Abstract][Full Text] [Related]
20. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]